Pharma companies dont lose exclusivity because they missed a deadline. They lose it because they mismanaged risk.
In generic-drug litigation, the real battleground isnt just the patentits the strategy around it. How you defend exclusivity, how you comm…

From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff
The market doesnt just move on innovationit moves on patent math. And for biopharma, few moments are as unforgiving as the composition of matter cliff: when the core p…

Pharmas patent cliff isnt just about expiration datesits about language.
Most people think the patent cliff is a calendar problem: a key patent expires, generics arrive, revenue falls. But in practice, the cliff is often a drafting problema quiet, tech…

The Patent Dance Is Not a DanceIts a Deadline. Heres How Biosimilar Developers Actually Win (or Lose) Before Court Ever Starts.
If youve ever watched a biosimilar case unfold, youve probably noticed the same pattern: the real fight doesnt begin in the …

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

Designing around formulation patents isnt just R&Dits a strategy game with real timelines, real risk, and real money.
In generic drug development, the hardest part isnt always finding a workable route to the active ingredient. Its navigating the …

Pharma forensics is having a momentand its not about lab coats. Its about reading the fine print.
In drug development, the public story is clinical trials, endpoints, and timelines. The private story is formulation: the how behind the what. And if you …